# Crossbow Therapeutics

Source: https://onco.cc/companies/crossbow-therapeutics/  
OnCo record `crossbow-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Crossbow Therapeutics makes antibody medicines that recognise fragments of proteins from inside cancer cells and pull the immune system's T cells onto them. Its first medicine is being tested in leukaemias and related blood cancers.

## Summary

Crossbow Therapeutics, Inc., based in Cambridge, Massachusetts, develops T-cell receptor mimetic (TCRm) antibodies that bind tumour peptides presented on HLA, built into T-cell engagers it calls T-Bolt molecules. It was founded, seeded and incubated at MPM BioImpact. The lead programme CBX-250 targets a cathepsin G peptide presented by HLA-A*02:01 and is in the CROSSCHECK-001 phase 1 trial (NCT06994676) in relapsed or refractory AML, higher-risk MDS, CMML and CML, given under the skin; the company dosed its first patient in September 2025. A second programme, CBX-663, targets a TERT-derived peptide on HLA-A*02:01 and entered a phase 1 trial (NCT07779798) in myeloid malignancies, advanced solid tumours and recurrent glioblastoma, with a first patient dosed in September 2026. The company launched in July 2023 with an 80 million US dollar Series A led by MPM BioImpact and Pfizer Ventures, and raised a 77 million US dollar Series B in March 2026 co-led by Taiho Ventures and Arkin Bio Capital. Its first registered cancer trial, NCT06994676, was posted on ClinicalTrials.gov in May 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.crossbowtx.com/

## Notes

- Founding year not stated on the company website; the July 2023 launch release says the company was founded, seeded and incubated at MPM BioImpact. Releases read on 29 October 2026.
- No clinical results have been read; the company expected initial CROSSCHECK-001 data around the end of 2026.

## Sources

- Official website: https://www.crossbowtx.com/
- Series B release, March 2026: https://www.crossbowtx.com/press-release-03-18-26
- Launch and Series A release, July 2023: https://www.crossbowtx.com/press-release-7-11-23
- ClinicalTrials.gov: CROSSCHECK-001 phase 1 trial of CBX-250 (NCT06994676): https://clinicaltrials.gov/study/NCT06994676
- ClinicalTrials.gov: phase 1 trial of CBX-663 (NCT07779798): https://clinicaltrials.gov/study/NCT07779798

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- companies: [MPM BioImpact](https://onco.cc/companies/mpm-bioimpact/), [Pfizer Ventures](https://onco.cc/companies/pfizer-ventures/), [Polaris Partners](https://onco.cc/companies/polaris-partners/)

---
JSON: https://onco.cc/api/v1/entities/crossbow-therapeutics.json